Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Period	ROE
2014-12-31	-171.57%
2016-12-31	-198.32%
2017-12-31	-382.82%
2018-12-31	-163.24%
2019-12-31	-224.48%
2020-12-31	-15.06%
2021-12-31	-20.15%
2022-12-31	-36.40%
2023-12-31	-59.42%
2024-12-31	-54.77%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDF	$1.56	+0.00%	0.92M
3
4
5

Cardiff Oncology Inc. (CRDF) Return on Equity (ROE)

ROE & ROA Data

Get Cardiff Oncology Inc. Data in Excel

More CRDF Financial Data